Biotech deals bounce back in DACH region

The DACH region saw 15 deals in the biotech space between January and the end of August this year, for an aggregate value of €170m. At the time of writing, a further two funding rounds had taken place in September: a €31.7m series-A for Immunic and a series-B round of €8m for Amal Therapeutics. This additional €39.7m takes the annual total to almost €210m, and at this rate 2017 looks on track to reverse the annual decline seen since 2014.

DACH has been a hotbed for biotech investment activity over the last five years, accounting for 131 (24%) of the 550 deals done in the space across the continent. This is second only to the UK & Ireland region, which saw 163 (30% of the 500 deals done).

Looking at the investors participating in these deals, there is a large presence of non-private-equity backers, and also of sector specialists. With biotech being a popular target for trade investors looking to back companies with potential to supplement their activities, the level of activity seen from these backers is not surprising.

The most active individual investor tracked by unquote" data is High-Tech Gründerfonds, a seed investment specialist based in Germany. Since 2012, the GP has done 292 deals, with its main focus being the software and computer services sector, where it has done 41% of its deals. Over the GP's history, however, it has invested €366m in the healthcare sector, slightly in excess of the €359m it has deployed in the technology space.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• DACH
• High-Tech Gründerfonds